Todd Yancey, MD
About Todd Yancey, MD
Todd Yancey, MD, is the Senior Vice President of New Market Development at BeiGene in the United States, with extensive experience in global medical affairs and clinical development roles.
Current Role at BeiGene
Todd Yancey, MD, is currently serving as the Senior Vice President of New Market Development at BeiGene in the United States. His role involves leading strategic initiatives to expand BeiGene's market presence. He has been with BeiGene in various capacities since 2017 and has a substantial impact on their continued growth and development in new markets.
Previous Positions at BeiGene
Before his current role, Todd held several senior positions at BeiGene. From 2019 to 2021, he was the Senior Vice President of Global Medical Affairs and New Market Development. Prior to that, from 2017 to 2019, he served as the Senior Vice President of Clinical Development - Immuno-Oncology. Both roles were based in the San Francisco Bay Area.
Experience at BioMarin Pharmaceutical Inc.
Todd Yancey worked at BioMarin Pharmaceutical Inc. as Group Vice President of Global Medical Affairs for a period of four months from 2016 to 2017, based in the San Francisco Bay Area. His short tenure was characterized by his involvement in medical affairs at a global level.
Academic Background and Medical Training
Todd Yancey, MD, holds a Doctor of Medicine (MD) from The University of Virginia School of Medicine, earned from 1982 to 1986. He completed his Internal Medicine Residency Program at The New York Hospital - Memorial Sloan Kettering Cancer Center from 1986 to 1989. Additionally, he completed a Fellowship in General Internal Medicine at Cornell University from 1989 to 1991. His undergraduate education was at The University of Virginia, where he earned a Bachelor of Arts (B.A.) in Biology and Psychology from 1977 to 1981.
Global Medical Affairs and Clinical Expertise
Todd has extensive experience in global roles, overseeing Medical Science Liaisons, Health Outcomes, and Scientific Communications. He has managed Medical Affairs data generation, including investigator-initiated trials and collaborations with organizations such as CTEP, MRC, CRUK, and international COOP groups. His expertise spans various therapeutic areas, including NSCLC, malignant melanoma, breast cancer, multiple myeloma, myelodysplastic syndrome, and colorectal carcinoma.